Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.

Date publication

mars 2024

Journal

The lancet. Healthy longevity

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KAMINSKY Marie-Christine

Tous les auteurs :
Guigay J, Ortholan C, Vansteene D, Cupissol D, Even C, Kaminsky MC, Sire C, Blot E, Debourdeau P, Bozec L, Saada-Bouzid E, Fayette J, Dalloz P, Pointreau Y, Caer HL, Falandry C, Digue L, Braccini A, Lopez S, Guillet P, Michel C, Cheurfa N, Schwob D, Bourhis J, Mertens C, Aupérin A,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38432247

Résumé

At present, there is no established standard treatment for frail older patients with recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the efficacy and safety of cetuximab to those of methotrexate (the reference regimen) in this population.

Mots clés

Humans, Male, Aged, Female, Methotrexate, adverse effects, Squamous Cell Carcinoma of Head and Neck, drug therapy, Cetuximab, adverse effects, Frail Elderly, Head and Neck Neoplasms, drug therapy, Disease Progression, Fatigue

Référence

Lancet Healthy Longev. 2024 03;5(3):e182-e193